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Cyanomorpholinoadriamycin (I PM) was reacted in a transcription buffer with DNA of an initiated transcription complex. Subsequent elongation 
of the initiated complex revealed permanent ranscriptional blockages at 16 sites after only 5 min of drug-DNA reaction time. The most dominant 
sites were immediately prior to 5’.CC (six) and 5’.GG (six) sequences of the non-template strand, consistent with the prer.:.;?ae of intrastrand 
crosslinking between adjacent guanine residues. Minor levels of blockage were at 5’.GC and 5’.CG sequences and may rctiect low levels of 
interstrand crosslinking. 
Cyanomorpholinoadriamycin: DNA: lntrastrand crosslink: Transcription; Sequence specificity 
1. INTRODUCTION 
Adriamycin. an anthracycline antibiotic with an ex- 
tremely rich biochemistry has been one of the most 
successful antitumour agents in clinical use throughout 
the last two decades [l-3]. Its use, however, has been 
restricted by several factors including cardiotoxicity 
(which limits the absolute irvei of drug administered to 
5.50 mg/m’). acquired drug resistance and inactivity of 
the drug against some tumours [2,3]. As a consequence 
of these limitations much research has been directed at 
the design of Adriamycin derivatives with improved an- 
titumour activity and fewer limiting properties [2-4]. 
The most promising derivative developed so far is 
the 3’-(3-cyano-4-morpholinyl)-3’-deaminoadriamycin 
(CMA) which has been shown to be up to 1400-fold 
more potent than Adriamycin in vitro [5,6] while retain- 
ing similar activity in experimental tumours [7]. The 
chemistry. biochemistry and biological responses of 
rMA have r~r~ntl~ been extensively rovicwo? hy Actrm _.... . . . . . . . . ._... , 
et al. [8]. Two major factors appear to contribute to the 
enhanced potency of CMA over Adriamycin. Firstly, 
the increased lipophylicity of CMA may facilitate the 
rapid passage of the drug into the cell and ultimately the 
nucleus. Once in the nucleus the second factor, the cya- 
nide moiety. has been suggested to act as a leaving 
group allowing covalent binding of the drug to DNA 
[WI. 
CMA has been shown to crosslink DNA in vitro 
[lo-141 with a preference for GC-rich DNA [15] and 
there is now good evidence that the cytotoxicity of 
CMA in vivo is directly related to the extent of inter- 
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strand crosslinks [8]. However, the sequence specificity 
of the interaction has yet to be established. 
In order to determine the nature of CMA crosslinking 
of DNA, we have utilised an in vitro transcription assay 
jl6,17] and present here the sequence specificity of 
CMA complexes with DNA established by the length of 
specific transcriptional blockages in this assay. The 
biockage sites are consistent ii;ith the formation of both 
intrastrand and interstrand crosslinks. 
2. EXPERIMENTAL 
CMA wasa gift from Dr. E.M. Acton (NCI. Washington). The drug 
was dissolved in DMF as a Z mM stock solution and stored in the dark 
at -20°C. E. co/i RNA polymerasc was from Pharmacia and all other 
rcagcnts were as described previously [IG]. 
2.2. Sortrcc of DNA 
The 497 bp PvrtlIlS~Jl restriction fragment containing the /UC UV5 
promoter was isolated from p8Wl as described previously [17]. 
An initiated transcription complex was formed (126~11) as described 
previously [l&17] using E. colt’ RNA polymcrase (32 units). 2 ~19 of 
497 bp DNA. 200 PM GpA. 5 PM GTP. CTP and ATP and [a- 
J’P]UTP in transcription buffer comprising 40 mM Tris (pH 8.0). 100 
mM KCI. 3 mM MgCI:. 0.1 mM EDTA. IO mM DTT. 0.125 m@ml 
acctylatcd BSA and I unit/~! RNasin. 
3.4. Rrcrcriurr 01’ CMA \tYrlr inirictred rrorwrijttiott cott~pks 
The initiated transcription complex was divided into two aliquots 
of SO/& 5//l of transcription buffer was added to one and 5~1 ofCMA 
(I PM final concentration) in transcription buffer was added to the 
other. The reactions wcrc incubated at 37OC and aliquots removed at 
spccifed tinics. 
2.5. LYongo riorr UJ /rmscri~triotl conrplcs 
The CMA-trcatcd initiated transcription complcxcs wcrc clongatcd 
for 4 min at 37°C by the addition of GTP, ATP. CTP and UTP at a 
final concentration of 2 mM in the prcsencc of 400 mM KCI. The 
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reaction was terminated by the addition of an equal volume of loading 
buffer as described previously [16.17]. 
2.6. Electropkorw.v and outormliogrcrpl~~ 
Electrophoresi:? was pcrformcd as described previously [16.17]. 
Transcriptional biozkages were detected and quantitated using a 400 
B Phosphorlmager (Molecular Dynamics. CA). 
3. RESULTS 
3. I. Reuction time 
Fig. I shows the effect of reaction time on the forma- 
tion of CMA-induced transcriptional blockages. Increa- 
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Fig. I, Transcriptional blockages induced by CMA. The drug (I PM) 
was rcactcd with initiated transcription complexes in transcription 
buffer (pH 8.0) at 37°C for times ranging frr-.n 0.5 to I20 min. The 
initiated complex is shown in lane I. while C and G dcnotc scqucncing 
lanes where transcription was terminated by mcthoxy-C’TP and 
mcthoxy-GTP, respcctivcly [Id-l 81. The control lanes rcprcscnt 
elongation of the initiated complex in the abscncc of added drug. 
Time (rmn) 
Fig. 2. Rate of reaction of CMA with DNA. The mole fraction of 
blocked transcripts (0, 37-mer; m. 43-mer) was calculated from the 
data shown in Fig. i, ad is shown at drug-DNA reaction times from 
0 to I20 min. The small panel shows the decay of full-length transcript 
from 0 to 20 min. 
sing reaction time of the initiated transcription complex 
with 1 PM CMA revealed transcription blockages not 
evident in the control lanes. The relative amount of 
RNA in each band was quantitated using a Phosphor- 
Imager, yielding the mole fraction of RNA correspond- 
ing to each blockage site. 
Blockages are evident after 5 min of incubation of the 
initiated transcription complex with CMA. The strong- 
est early blockages. yielding RNA 37 and 43 nucleotides 
long. increased linearly as a function of reaction time 
for 30 min and reached a maximal level after approx- 
imately 1 h (Fig. 2). The cumulative effect of blockages 
at different sites reduced the fu!l-!ength transcript to 
zero after approximately 20 min, with a half-life of ap- 
proximately 2 min under these conditions. 
The sequence specificity of the binding of CMA to 
DNA under in vitro transcription conditions is present- 
ed in Fig. 3. Assignment of bands in the region of lOO- 
140 nucleotides was performed on a separate gel sub- 
jected to double the electrophoresis time (data not 
shown). Analysis of the drug blockage sites reveals 5 
major features. In the 380 bp probed by this procedure. 
16 blockage sites are well resolved in the 120 bp region 
from 20-140. with 6 of these occurring at 5’-CC sequen- 
ces (non-template strand). 6 at 5’-GG sequences, 3 at 
5’-GC and one at 5’-CG. The strongest blockages (mole 
fraction of RNA >0.05) were at 5’-CC (sites 3, 9. 10 and 
16) and 5’-GG (site 12). The single most dominant 
blockage site is at 5’-CC (site 3) and is clearly more 
lethal than neighbouring S-GG sites at 1, 4 and 5. 
Almost all blockages are one nucleotide prior to the 
consensus blockage sequences hown in Fig. 3. and this 
is consistent with transcriptional blockage patterns ob- 
served previously for other DNA-acting drugs [18,19]. 
Only weak blockages are apparent at 5’-GC and 5’-CG 
sites (2, 6-8). 
All of the major blockages shown in Fig. 3 wcrc 
permanent in that no progression of RNA polymcrasc 
was evident at any site for elongation times up to one 
hour (data not shown). 
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Fig. 3. Sequence specificity of blocked transcripts. The mole fraction of blocked transcrip:s (30 min reaction time of Fig. I) is shown at each 
nucleotide in the transcribed sequence up to transcripts of 140 nucleotides in length. 
4. DISCUSSION 
4.1. Seyire,rce spec$city 
Since the dominant blockage sites were all at (or im- 
mediately prior to) 5’-CC or 5’-GG (non-template) sites. 
it appears that these are the major sites of interaction 
of CMA with DNA in vitro. From the present results 
it is not possible to conclude whether adducts are on the 
template or non-template strand. However. because of 
the known accessibiIity and reactivity of guanine N-2 
and N-7 positions [20], the known reaction of guanine 
with alkylators and drugs [21,22], and the limited reacti- 
vity of cytosine [20.21]. it is highly likely that the ad- 
ducts are at 5’-GG of both the template and non-tem- 
plate strands (i.e. blockages at 5’-CC of the non-tem- 
plate strand arise from adducts at 5’-GG of the template 
strand, whereas blockages at 5’-GG of the non-template 
reflect adducts on that strand). For these reasons we 
conclude that all of the major transcriptional blockages 
arise from CMA adducts at adjacent guanine residues. 
and this is indicative of intrastrand crosslinking. The 
absolute requirement for adjacent guanine residues is 
also highlighted by the lack of significant transcriptio- 
nal blockages at any isolated G residues, irrespective of 
whether on the non-template or template strand. 
If the major blockages at 5’-CC and 5’-GG (non- 
template) sequences represent intrastrand crosslinking 
at adjacent G-residues. as discussed above, then the 
minor blockages at 5’-GC probably reflect interstrand 
crosslinking sites. It has been well documented recently 
that high levels of intrastrand crosslinks form with 
DNA in vitro in the absence of metabolic activation 
[12.14,15]. at CMA concentrations in the micromolar 
range and for reaction times up to 100 min. By compa- 
rison, intcrstrand crosslinking involving metabolic acti- 
vation occurs more rapidly even at concentrations its 
low as 10-” M [ 131. it thcrcforc appears likely that 
intcrstrand crosslinking is mctnholically activated in 
vivo and thitt on!y low lcvcls arc dctectcd in vitro unless 
substantially higher concentrations of CMA are em- 
ployed. Apparently intrastrand crosslinking in vitro is 
substantially more favoured than interstrand crosslink- 
ing but this may not be the case in vivo. 
The observation that all transcriptional blockage 
sites were at 5’-CC. GG, GC or CG sequences indicates 
that the extent of intrastrand crosslinking should be 
highly dependent on the (G+C) content of any DNA, 
irrespective of the exact nature of the sequences in- 
volved with interstrand crosslinking. Such a dependence 
has recently been reported by Jesson et al. [ 151 using the 
ethidium bromide fluorescence assay. and is consistent 
with the present in vitro transcriptional results. 
Although the role of the cyano group has been well 
established as important for interstrand crosslinking. 
both in vitro and in vivo [8.9,12], and the sequence 
specificity of the sites has now been defined, it is still not 
possible to suggest with confidence the nature of the 
second attachment site. The reduced extent of intra- 
strand crosslinking by the 5-imino derivative of CMA 
has demonstrated that the quinone moiety serves some 
role in interstrand crosslinking [ 151. Other mechanisms 
and structures have been suggested to account for cross- 
linking [8.9] and it will now be possible to test the va- 
lidity of these structures based on the apparent assign- 
ment of S-GG intrastrand crosslinks and tentative 5’- 
GC interstrand crosslinks. 
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